Literature DB >> 22224185

Modelling Factors Causing Mortality in Oesophageal VaricesPatients in King Abdul Aziz University Hospital.

Sami Bahlas1.   

Abstract

OBJECTIVES: The objective of this study is to reach a model defining factors precipitating short survival in patients with oesophageal varices and improving the understanding of such factors. Models would help to prioritize the clinical goals and intervention for saving the lives of patients.
METHODS: Retrospective analysis of all patients admitted to King Abdul Aziz University Hospital who had been diagnosed with oesophageal varices. The patients' demographics, disease history, physical examination, viral infections, parasitic infections, blood pictures, cancer biomarkers, liver enzymes and bleeding details were collected, tested for correlation with mortality to formulate a model.
RESULTS: A total of 148 patients were included in this study. 37 clinical variables were studied only 15 factors were found to have a statistical significance. These factors were PT (RC=0.17338 P-value 0.00011), APTT (RC=0.07916, P-value 0.00002), haemoglobin level (RC=-0.44748, P-value <0.0001), WBC (RC = 0.22255, P-value 0.00001), serum albumin level (RC=-0.12953, P-value 0.00001), serum creatinine (RC=0.01483, P-value 0.00002), at least one incidence of encephalopathy (RC=1.80500, P-value 0.00014), total bilirubin (RC=0.01371, P-value 0.00016), direct bilirubin (RC=0.01298, P-value 0.00357, serum AST (RC=0.00914, P-value 0.00462), presence of at least bleeding event (RC=1.03373, P-value 0.00613), ascites grade I (RC=-1.57435, P-value 0.00967), SBP (RC=1.47216, P-value 0.01581), platelets count (RC=0.00398, P-value 0.03476) and oesophageal varices (RC = -1.42139, P-value 0.03673). Only 5 factors were likely to affect the mortality status. These factors were encephalopathy, spontaneous SBP, bleeding, ascites and grade of oesophageal varices. Six models were then formulated.
CONCLUSION: These models should be retested in larger study groups to test their reliability in order to use them as surrogate end point in future clinical studies.

Entities:  

Year:  2009        PMID: 22224185      PMCID: PMC3251181          DOI: 10.5001/omj.2009.39

Source DB:  PubMed          Journal:  Oman Med J        ISSN: 1999-768X


  7 in total

1.  Well informed uncertainties about the effects of treatments.

Authors:  Iain Chalmers
Journal:  BMJ       Date:  2004-02-28

2.  Absence of evidence is not evidence of absence.

Authors:  Phil Alderson
Journal:  BMJ       Date:  2004-02-28

Review 3.  Management of gastrointestinal bleeding in patients with cirrhosis of the liver.

Authors:  Jaime Bosch; Juan G Abraldes
Journal:  Semin Hematol       Date:  2004-01       Impact factor: 3.851

Review 4.  Variceal bleeding and portal hypertensive gastropathy.

Authors:  L Dagher; A Burroughs
Journal:  Eur J Gastroenterol Hepatol       Date:  2001-01       Impact factor: 2.566

Review 5.  Coagulation disorders in liver disease.

Authors:  Lucio Amitrano; Maria A Guardascione; Vincenzo Brancaccio; Antonio Balzano
Journal:  Semin Liver Dis       Date:  2002-02       Impact factor: 6.115

Review 6.  Somatostatin analogues for acute bleeding oesophageal varices.

Authors:  Peter C Gøtzsche; Asbjørn Hróbjartsson
Journal:  Cochrane Database Syst Rev       Date:  2008-07-16

Review 7.  Antacids for preventing oesophagogastric variceal bleeding and rebleeding in cirrhotic patients.

Authors:  J Yang; Z Guo; Z Wu; Y Wang
Journal:  Cochrane Database Syst Rev       Date:  2008-04-16
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.